Announcement of Analytical Validation for SPOT-MAS on Five Cancers Lacking Standard Screening (LSS)

We previously developed a SPOT-MAS assay to capture ctDNA signatures from 05 common cancer types (breast, lung, liver, colorectal, and stomach) and successfully facilitated early-stage detection in both retrospective (1) and prospective validation (2) studies.

The recent study published in Future Oncology, “Evaluation of a Multimodal ctDNA-Based Assay for Detection of Aggressive Cancers Lacking Standard Screening Tests”, extends the analysis to the 05 lethal LSS (lacking standard-of-care screening) cancers: endometrial, esophageal, head and neck, ovarian and pancreatic (3).

The study revealed numerous shared ctDNA signals across 05 common cancers and 05 LSS cancers, demonstrating that SPOT-MAS could detect new lethal cancers with 96.2% specificity and 74.8% overall sensitivity.

This proof-of-concept study shows that SPOT-MAS, a non-invasive test trained on five common cancer types, could detect a number of LSS cancer cases, potentially complementing existing screening programs.

Read the detailed publication summary here: https://spotmas.com/blog/evaluation-of-a-multimodal-ctdna-based-assay-for-detection-of-aggressive-cancers-lacking-standard-screening-tests/

#GeneSolutions #CancerDetection #FutureOncology #SPOTMAS #CancerResearch #EarlyDetection

 

🔑 References:

(1) Le Son Tran et al. Analytical and clinical validation of a circulating tumor DNA–based assay for multicancer early detection.. JCO 42, 10548-10548(2024).DOI:10.1200/JCO.2024.42.16_suppl.10548

(2) Nguyen, H., Luong, B. A., Tran, D., Nguyen, T., Ngo, Q. D., Le, L. G. H., Ho, Q. C., Nguyen, H. T., Nguyen, C. M., Tran, V. U., Pham, T. V. N., Le, M. T., Le, N. a. T., Le, T. K., Nguyen, T. L., Pham, H. T., Le, H. T., Duong, H. D. T., Hoang, A. V., . . . Tran, D. T. (2021). Ultra-Deep Sequencing of Plasma-Circulating DNA for the Detection of Tumor- Derived Mutations in Patients with Nonmetastatic Colorectal Cancer. Cancer Investigation, 40(4), 354–365. https://doi.org/10.1080/07357907.2021.2017951

(3) Van Thien Nguyen, C., Nguyen, T. H. H., Vo, D. H., Van, T. T. V., Nguyen, G. T. H., Tran, T. H., Nguyen, T. H., Huynh, L. a. K., Nguyen, T. D., Tran, N., Ha, T. M. T., Le, P. T. Q., Truong, X. L., Nguyen, H. L., Tran, U. V., Hoang, T. Q., Nguyen, V. B., Le, V. C., Nguyen, X. C., . . . Tran, L. S. (2024). Evaluation of a multimodal ctDNA-based assay for detection of aggressive cancers lacking standard screening tests. Future Oncology, 1–11. https://doi.org/10.1080/14796694.2024.2413266

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More